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Enhanced Bruton’s tyrosine kinase in B-cells
and autoreactive IgA in patients with
idiopathic pulmonary fibrosis
Peter Heukels1,5* , Jennifer A. C. van Hulst1, Menno van Nimwegen1, Carian E. Boorsma2, Barbro N. Melgert2,6,
Jan H. von der Thusen3, Bernt van den Blink4, Rogier A. S. Hoek1, Jelle R. Miedema1, Stefan F. H. Neys1,
Odilia B. J. Corneth1, Rudi W. Hendriks1, Marlies S. Wijsenbeek1 and Mirjam Kool1*
Abstract
Rationale: Idiopathic Pulmonary Fibrosis (IPF) is thought to be triggered by repeated alveolar epithelial cell injury.
Current evidence suggests that aberrant immune activation may contribute. However, the role of B-cell activation
remains unclear. We determined the phenotype and activation status of B-cell subsets and evaluated the
contribution of activated B-cells to the development of lung fibrosis both in humans and in mice.
Methods: B-cells in blood, mediastinal lymph node, and lung single-cell suspensions of IPF patients and healthy
controls (HC) were characterized using 14-color flow cytometry. Mice were exposed to bleomycin to provoke
pulmonary fibrosis.
Results: More IgA+ memory B-cells and plasmablasts were found in blood (n = 27) and lungs (n = 11) of IPF
patients compared to HC (n = 21) and control lungs (n = 9). IPF patients had higher levels of autoreactive IgA in
plasma, which correlated with an enhanced decline of forced vital capacity (p = 0.002, r = − 0.50). Bruton’s tyrosine
kinase expression was higher in circulating IPF B-cells compared to HC, indicating enhanced B-cell activation.
Bleomycin-exposed mice had increased pulmonary IgA+ germinal center and plasma cell proportions compared to
control mice. The degree of lung fibrosis correlated with pulmonary germinal center B-cell proportions (p = 0.010,
r = 0.88).
Conclusion: Our study demonstrates that IPF patients have more circulating activated B-cells and autoreactive IgA,
which correlate with disease progression. These B-cell alterations were also observed in the widely used mouse
model of experimental pulmonary fibrosis. Autoreactive IgA could be useful as a biomarker for disease progression
in IPF.
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Background
Idiopathic Pulmonary Fibrosis (IPF) is a progressive and
ultimately fatal disorder [1, 2]. Although the natural his-
tory of patients with IPF varies from rapid progressive to
episodes of relative stability for years, the median survival
is 3–5 years following diagnosis [3]. Fibrosis in IPF pa-
tients is considered the end-result of exaggerated wound
repair due to repetitive subclinical epithelial injury, leading
to (myo-)fibroblast activation and uncontrolled matrix de-
position [4]. Current disease modifying therapy consists of
two drugs that slow down progression of fibrosis [5, 6].
Despite all evidence that immunity is also involved in IPF
pathogenesis, treatments that modulate inflammation
have failed or even had deleterious effects on primary
end-points in clinical IPF trials [7]. It is a topic of debate
to what extent immunity is a (co-)driver of disease or
whether it is merely an epiphenomenon which can
correlate with disease severity.
Recently, several lines of evidence suggest a role for
B-cell immunity [8, 9]. Firstly, tertiary lymphoid
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organs (TLOs) have been found in lungs of IPF pa-
tients, which persist and accumulate during disease
progression [10, 11]. TLOs harbor a distinct T-cell
and B-cell zone, and attraction of B-cells into TLOs
depends on CXCL13 [12]. CXCL13 was reported to
be elevated in lungs and serum of patients with IPF
[12, 13]. Secondly, over the past two decades several
specific auto-antibodies have been identified in IPF8,
likely involving local production of (auto)-antibodies
in lung TLOs. Autoreactive antibodies, recognizing
pulmonary proteins, may also contribute to repeated
lung injury [8]. Thirdly, elevated serum B-cell acti-
vating factor (BAFF) was indicative for worse disease
outcome in IPF patients [14].
A role for B-cell immunity in IPF may be especially
relevant because new therapies that (only) target B-cells or
decrease antibody production are effective in other B-cell-
mediated interstitial lung diseases and possibly in acute
exacerbations of IPF [15–17]. Whether dual treatment of
available anti-fibrotic drugs with anti-inflammatory therap-
ies targeting B-cell activation is beneficial in IPF is currently
unknown. Hence, we need a better understanding of B-cell
profiles in blood and especially in lungs of IPF patients.
Therefore, we performed an in-depth analysis of B-cell
phenotype and activation status in blood, mediastinal
lymph nodes (LN), and lungs of IPF patients and con-
trols. We analyzed total and/or autoreactive antibodies
in plasma and lungs of IPF patients and identified im-
munological biomarkers for disease progression. Finally,
we investigated B-cell subsets in a bleomycin-induced
pulmonary fibrosis mouse model.
Methods
Study design and subjects
Human lung and Lymph Node (LN) tissue were collected
from patients with IPF undergoing lung transplantation.
IPF was diagnosed according to current guidelines of the
ATS/ERS/JRS/ALAT [1, 18]. All explanted lungs fulfilled
pathological criteria for an usual interstitial pneumonia
(UIP). As a control, lung tissue was obtained from volume
reduction procedures during transplantation upon size mis-
match of oversized donor lungs or residual material ob-
tained during surgery for pulmonary tumors. Control
residual lung tissue was taken at least > 3 cm from the
tumor. For this, only patients with a normal pulmonary
function test or mild airflow obstruction (GOLD 1) without
emphysema were selected. Control LN were collected from
lung transplantation donors. Blood samples were obtained
after patient’s informed consent. All patient and healthy
subject characteristics are shown in Table 1. The Medical
Ethical Committee of the Erasmus MC Rotterdam ap-
proved this study (METC 2012–512) and gave consent for
collection of residual material of explanted lungs and LN.
Human tissue and blood processing
Fresh lung and LN tissues were stored in cold phosphate
buffered saline (PBS) and processed within 24 h follow-
ing transplantation or resection.
Lung resection specimens were rinsed with PBS to re-
move residual blood. After mincing the lung, specimens
were enzymatically digested in digestion medium (Life
Technologies) with 10μg Liberase (Roche, LiberaseTM)
and 40 Units of DNA-se (Roche, DNase I recombinant,
RNase-free) for 30min in a humidified incubator at 37 °C
while gently shaking the samples. The remaining cell debris
was removed by passing the cells through a 100 μm-diam-
eter disposable cell mesh filter. Fresh LN were separately
past through a 100 μm-diameter disposable cell mesh filter.
Single cell suspensions specimens were washed in Roswell
Park Memorial Institute medium (RPMI) with 5% fetal calf
serum and centrifuged for 10min at a speed of 400×g. Lung
single cell suspensions were also subjected to red blood cell
lysis, washed and counted. Finally, all samples were
aliquoted and cryopreserved .
Blood samples were collected in ethylenediaminetetraacetic
acid (EDTA) tubes (BD Vacutainer K2E). Peripheral blood
mononuclear cells (PBMCs) and plasma were obtained,
processed and stored according to standard protocols [19].
PBMCs and single-cell suspensions were stained for
extra- and intracellular markers described in Additional
file 10: Table S1. PBMCs and single cell suspensions
were stained with antibodies for extra- and intracellular
markers described in Additional file 10: Table S1. To
control for non-specific labeling Fc-block (Anti-Mouse
CD16/CD32 Fc Block) was used. Fixable Viability Dye
eFluor 506 (eBiosciences) was applied as a live-dead
marker. In short, cells for the B-cell staining were incu-
bated in FACS buffer (PBS, 0.25% BSA, 0.5 mM EDTA,
0.05% NaN3 sodium azide) and for the T-cell staining in
MACS buffer (0.5% BSA + 2mM EDTA in PBS) with
fluorescent antibodies for 60 min at 4 °C using methods
recommended by the manufacturers. Cells for the T-cell
staining underwent a second extracellular incubation
step for antibodies with Brillaint Viotet (BV) conjungates
in BV-bufferin Brilliant Stain-buffer (BD Biosciences,
cat#563794). After fixation and permeabilization (2%
paraformaldehyde solution and 0,5% saponin (Quillaja
Bark, Sigma cat#S7900) cells were incubated with the
Bruton’s tyrosine kinase (BTK)-antibody or Isotype con-
trol in Saponine buffer for 60 min at 4 °C (only B-cell
staining). Biotinylated antibodies were visualized with
streptavidin-BV650. Cells were measured on a LSRII
Flow cytometer (BD Biosciences). We analyzed a mini-
mum of 200,000 alive cells for blood samples and 100,
000 alive cells for the lung tissue samples for cytometric
analysis. Data was analyzed by FACS Flow-Jo software.
To compare mean fluorescence intensity (MFI) values
between experiments, identical control samples (n = 3)
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were measured in each (subsequent) experiment for
standardization.
Immunohistochemistry
Immunohistochemical analyses were performed accord-
ing to standard procedures [19]. Antibodies used are
listed in Additional file 10: Table S1.
Self-reactive and total immunoglobulin (Ig) G, IgM and
IgA
HEp-2 analyses and enzyme-linked immunosorbent
assay (ELISA) on plasma samples were performed ac-
cording to standard procedures. Serum samples (1/50
diluted) of IPF patients and healthy controls (HC)
were incubated for 1 h on Kallestad human epithelial
cell (HEp-2) slides (Bio-Rad Laboratories). As detec-
tion antibodies Ig F (ab’)2 fragments were applied to
the HEp2 slides (Additional file 10: Table S1). The
fluorescence intensity of HEp2 slides was evaluated
using a LSM 311 META confocal fluorescence micro-
scope (Zeiss) and LSM Image Browser Version
4.2.0.12 software (Zeiss) in an automated and thus
independent manner. The fluorescence intensity was
corrected for number of cells per slide. A positive
HEp-2 result was set on 2SD above the mean of the
HC for each immunoglobulin subtype.
Mice
Mice were bred and kept under specified pathogen-free
conditions in the Erasmus MC experimental animal
Table 1 Patient and healthy subject characteristics
Blood Lung MLN
HC (n = 21) IPF (n = 27) Control (n = 9) IPF (n = 11) Control (n = 13) IPF (n = 10)
Age, years (95% CI) 56 (52–61) 70 (67–73) 50 (56–66) 59 (55–63) 59 (56–61) 58 (53–61)
Gender: M/F (n, (%)) 12 (57%) /9 19 (70%)/8 5 (55%)/4 9 (81%)/2 8 (62%)/5 9 (90%)/1
Diagnosis
-MDD: IPF/Prob IPF/Pos IPF(n, (%)) 22 (81%)/5/0 11 (100%)/0/0 10 (100%)/0/0
PA obtained (%) 22 100 100
History
-Cardiovascular disease (n, (%))* 0 14 (51%) 3 (33%) 2 (18%) 2 (20%)
-Auto-immune disease (n, (%))# 0 1 (3%) 1 (11%) 0 (0%) 0 (0%)
PFT, percentage predicted (95% CI)
-TLCO 47 (42–53) 86 (76–95) 33 (27–39) 34 (27–40)
-FVC 77 (72–83) 108 (95–121) 53 (45–60) 52 (44–60)
-FEV1/FVC 69 (63–73)
COPD (n) (stage) 0 3 (all GOLD1) 0 0
Smoking, n (%)
-never 5 (19%) 2 (22%) 2 (18%) 2 (20%)
-former 22 (81%) 7 (78%) 9 (82%) 8 (80%)
-current 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Medication
-prednisone use: (n, (%)) 8 (30%) 0 (0%) 4 (36%) 3 (30%)
dose (mg/day)
> 10mg/d 0 (0%) 1 (9%) 0 (0%)
</= 10 mg/d 8 (30%) 3 (27%) 3 (30%)
pa Other immunosuppressive (n, (%)) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
PO Please Pirfenidone (n, (%)) 0 (0%) 2 (18%) 2 (20%)
Nintedanib (n, (%)) 1 (3%) 3 (27%) 3 (30%)
* IPF patients (blood): Hypertension (n = 9), ischemic cardiac disease (n = 5), or transient ischemic attack (n = 2), Control lung: Hypertension (n = 3), Cerebro Vasculair
Accident (n = 2)
IPF lung and LN: Hypertension and transient ischemic attack (n = 1), Hypertension (n = 1)
# IPF patients (blood): colitis ulcerosa (not active and no immunomodulating medication) (n = 1)
Control lung: Rheumatoid arthritis (not active and no immunomodulating medication) without lung involvement or anti-CCP antibodies (n = 1)
Abbreviations: MLN =mediastinal lymph node, MDD =multidisciplinary diagnosis, PFT = pulmonary function test, TLCO = carbon monoxide transfer factor, FVC =
forced vital capacity, FEV1 = forced expiratory volume in one 1 s
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facility. All experimental protocols have been reviewed
and approved by the Erasmus Medical Center Commit-
tee of animal experiments. Procedures of mouse experi-
ments are described in Additional methods 1.
Statistics
Statistical analysis was performed using IBM SPSS
Statistics 21 and GraphPad Prism 6 software. For calcu-
lating the level of significance of differences between
groups we used the Mann-Whitney U test. Correlation
coefficients were calculated using Spearman’s rank
method. P values < 0.05 were considered significant.
Flow cytometry data is either represented as percentage
population or as MFI.
Results
Alterations in B-cell subsets in blood, LN and lungs of IPF
patients
We first evaluated different B-cell subsets in blood,
explanted lungs, and LN of IPF patients. We quantified
naïve B-cells (IgD+ CD27−), IgD+ and IgD− memory
CD27+ B-cells, double negative (DN) B-cells (IgD−CD27−),
transitional B-cells (CD19+CD24+CD38+), and plasma-
blasts (CD19+CD38+CD27+), following the gating strategy
in Fig. 1 A.
The numbers and percentages of total B-cells in blood,
LN, and lung were similar between IPF patients and
controls (Additional file 1: Figure S1). The proportions
of naïve B-cells were higher in blood than in lung, but
did not differ between control and IPF (Fig. 1 B /C). In
the circulation, IPF patients had a lower frequency of
transitional B-cells, but significantly higher proportions
of DN memory B-cells and plasmablasts compared with
HC (Fig. 1 B). IPF lungs harbored higher proportions of
transitional B-cells and plasmablasts compared to con-
trol lungs (Fig. 1 C). No alterations in B-cell subsets
were observed between IPF LN and control LN
(Additional file 2: Figure S2).
Augmented proportions of IgA-expressing memory B-cell
subsets
We next evaluated surface immunoglobulin (Ig) expres-
sion on memory B-cell subsets in blood and single-cell
suspensions of explanted IPF lungs. Surface IgM and
IgG expression was evaluated on IgD− memory B-cells
and DN-memory B-cells (Fig. 2 A) as depicted in a rep-
resentative blood and lung sample from an IPF patient
and a healthy control in Fig. 2 B. The IgD−IgM−IgG−
memory and IgM−IgG− DN-memory B-cells were
enriched for IgA surface expression (Additional file 3:
Figure S3 and Additional file 4: Figure S4). These
populations are hereafter called IgA+ memory B-cells.
The proportion of IgA+ cells within the CD27+ mem-
ory B-cell fraction was significantly higher in IPF
patients in blood (~ 44%, compared to ~ 30% in con-
trols) and in the lung (~ 60% versus ~ 40%, respectively)
(Fig. 2 C). Likewise, within in the DN-memory B-cells,
the IgA+ population was significantly higher in blood of
IPF patients compared to controls (Fig. 2 D). Within
both memory B-cell populations, this increase of IgA+
B-cells was at the expense of IgM+ B-cells in blood and
at the expense of IgG+ B-cells in lungs (both significant)
(Fig. 2C, D; Additional file 3: Figure S3 and Additional
file 4: Figure S4). No differences in surface Ig expression
on memory B-cell subsets were observed between
explanted IPF and control LN (Additional file 3: Figure
S3 and Additional file 4: Figure S4).
Summarizing, within the two memory populations in
blood and lung, IgA-expressing B-cells were increased in
IPF patients and dominant over B-cells expressing other
Ig subclasses.
IgA+ B cells are present within TLO structures of IPF lungs
We next examined whether IgA expressing B-cells are
present within TLOs found in IPF lungs [11]. In the
lungs of our IPF patient cohort numerous TLOs could
be detected (Fig. 3 A). We next confirmed that IPF
TLOs had a specific organization with segregated T and
B-cell zones (Fig. 3 B). Within the B-cell area, IgG stain-
ing was weak, however IgA staining was strong (Fig. 3
C). IgA could also be detected outside TLOs, likely
reflecting secreted IgA.
Thus, IgA+ B-cells were present in TLO in IPF lungs
and probably contribute to the local IgA production.
More activated follicular helper T-cells (Tfh) in IPF lungs
Active TLOs contain germinal centers (GCs) in which
follicular T helper (Tfh) cells provide essential help to
B-cells to promote their activation. Tfh-cells, identi-
fied as CD3+CD4+CXCR5+CD45RA− cells, were eva-
luated for the expression of PD-1, which is a reliable
marker for activated Tfh-cells (Fig. 4 A) [20]. The
proportions of Tfh-cells as percentage of CD4+ T-
cells did not differ between HC and IPF patients
(blood and lung, data not shown). PD-1 expression
was low in IPF and control blood, but was higher in
IPF lung tissue (Fig. 4 A, B). Hereby the proportions
of activated PD-1high Tfh-cells in IPF lungs was sig-
nificantly higher compared to control lungs (Fig. 4
C), consistent with the presence of active GCs in
pulmonary TLOs.
Autoreactive IgA and IgG levels are higher in IPF and
autoreactive IgA correlates with disease progression
Total IgG and IgA – but not IgM – was significantly
higher in plasma of patients with IPF compared with
HC (Additional file 5: Figure S5). To explore the
presence of auto-antibodies in plasma from IPF
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patients, we evaluated HEp-2 staining patterns and
their fluorescence intensity for IgM, IgG and IgA.
The staining patterns revealed the presence of auto-
reactive IgG and IgA, mainly recognizing nuclear
antigens and showing a homogeneous staining across
the nucleoplasm. Quantification of the autoreactive
IgG and IgA fluorescence intensities, reflecting their
plasma concentrations, revealed a significant increase
in plasma of IPF patients compared to HC (Fig. 5 B).
Also, the proportion of IPF patients harboring auto-
reactive IgM, IgG, or IgA was increased compared to
HC (Fig. 5 A, B). There was no correlation between
total and autoreactive IgG/IgA levels (Additional file
5: Figure S5). In ~ 48% of the IPF patients detectable
autoantibodies were present versus in 18% of the HC,
being IgM, IgG, or IgA (Fig. 5 C). Interestingly,
Fig. 1 Alterations in B-cell subsets in blood, LN and lungs of IPF patients. ((a) Representative gating strategy for identification of B-cell subsets in
blood and single cell suspensions of lungs. Naïve B-cells (CD19+IgD+CD27-) IgD+ and IgD− memory CD27+ B-cells, double negative (DN) B-cells
(CD19+IgD−CD27−), transitional B-cells (CD19+CD24+CD38+), and plasmablast (CD19+CD38+CD27+) were identified. (b) c Percentage of circulating
B-cell subsets of total B cells in HC (n = 21) and IPF patients (n = 27). (c) Proportion of B-cell subsets of total B-cells in single cell suspensions of
control lungs (n = 9) and explanted IPF lungs (n = 11). Non-parametric two-tailed Mann-Whitney test was used. Data are expressed as mean and
dots represent individual patient values. * P < 0.05 ** P < 0.01 *** P < 0.001
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within the IPF patients that had autoreactive anti-
bodies, a majority (~ 62%) had autoantibodies of mul-
tiple isotypes.
We next evaluated whether levels of circulating auto-
antibodies correlated with measures of disease progres-
sion. No correlation was observed between auto-reactive
IgG or IgM with 1-year forced vital capacity (FVC)
change (Additional file 6: Figure S6). However, higher
amounts of autoreactive IgA correlated with an
increased decline of FVC (Fig. 5D).
In summary, about half of the IPF patients analyzed
had circulating IgM, IgG or IgA anti-nuclear auto-
antibodies (ANAs), whereby autoreactive IgA correlated
with disease progression.
Increased Bruton’s tyrosine kinase expression levels in B
cells of IPF patients
Given the reported increased protein expression of the
signaling molecule Bruton’s tyrosine kinase (BTK) in B-
cells from patients with various autoimmune disorders,
such as rheumatoid arthritis, Sjogren’s Syndrome and
vasculitis [21], we next evaluated BTK expression in
circulating B-cells by intracellular flow cytometry. We
observed higher BTK protein levels in IPF compared to
HC (Fig. 6 A). Specifically, naïve B-cells showed the
most pronounced enhanced BTK expression in IPF
patients (Fig. 6 B). We found no difference in BTK levels
between treatment-naïve patients and patients using
low-dose prednisone (data not shown). In lungs and LN
Fig. 2 Augmented proportions of IgA-expressing memory B-cell subsets. (a) Representative gating strategy for the identification of
immunoglobulin surface expression (IgM or IgG) on IgD− memory B-cells CD19+CD27+IgD−) or double negative (DN) B-cells (CD19+CD27−IgD−).
(b) Gating strategy as described in panel A for a representative blood and lung sample for a control and IPF patient. (c; left) Pie chart showing
the distribution of surface expression of IgD, IgM, IgG, and IgA on CD27+ memory B-cells depicted with mean percentage; (c: right) Proportions
of IgA+ memory B-cells of total CD27+ memory B-cells in blood and lung samples. (D; left) Distribution of immunoglobulin expression of IgM, IgG
and IgA on DN memory B-cells depicted in a pie-chart with mean percentage. (d; right) Proportions of IgA+ DN memory B cells of total DN B-
cells in blood and lung samplesNon-parametric two-tailed Mann-Whitney test was used. Data are expressed as mean and dots represent
individual patient values. ** P < 0.01 *** P < 0.001.
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of IPF patients, BTK expression in B-cell subsets was
similar to controls (Fig. 6 C).
Taken together, our data demonstrate that in blood of
IPF patients, BTK expression in B-cells was higher than
in HC.
Bleomycin-induced IgA+ induction and GC B-cells
correlate with fibrosis scores in a mouse model
To explore if changes seen in human B-cell subsets would
also occur in a well-established mouse model for fibrosis,
we subjected C57Bl/6 mice to bleomycin or saline (control
group). Histological analysis revealed that pulmonary fi-
brosis was present in mice 21 days after bleomycin expos-
ure (Fig. 7 A). Lungs of bleomycin-exposed mice
contained inflammatory aggregates with a core of GL-7+
GC B-cells and a ring of IgD+ naïve B cells (Fig. 7 A).
Blinded histopathology scoring confirmed that the total fi-
brosis score (TFS) was elevated in the bleomycin-exposed
group (Fig. 7 B). Next, we evaluated B-cell subsets in lungs
by flow cytometry (Fig. 7 C and Additional file 7: Figure
S7). The frequency of pulmonary GC B-cells and plasma
cells of alive cells were significantly higher in mice
exposed to bleomycin compared to saline-exposed mice.
Within GC B-cells or plasma cells respectively, the
proportions of pulmonary IgA+ GC B-cells and IgA+
plasma cells were increased (Additional file 8: Figure S8).
In bleomycin-exposed mice, the TFS and the frequency of
bronchoalveolar lavage fluid (BALF) GC B-cells showed a
positive correlation (Fig. 7D).
In summary, mice subjected to bleomycin-induced
pulmonary fibrosis showed similar pathobiological
changes as in human IPF. The extent of fibrosis corre-
lated with the proportion of BALF GC B-cells.
Discussion
Our study assessed B-cell subsets and their activation sta-
tus in IPF lungs and LN by 14-color flow cytometry. We
observed that IPF patients had increased plasmablasts and
Fig. 3 IgA+ B cells are present within TLO structures of IPF lungs. (a) Hematoxylin and eosin (h&e) staining of a control lung and IPF lung
showing numerous TLOs (black arrows). (b) Pulmonary TLOs of IPF lung stained with anti-CD3 (T cells) and anti-CD20 (B-cells). (c) Representative
images of staining with anti-IgG and anti-IgA. Magnification: 10x (a) and 40x (b and c)
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IgA+ memory B-cells in blood, intense IgA staining in
lung TLOs, and more serum IgA antibodies recognizing
nuclear self-antigens. Higher autoreactive IgA levels corre-
lated with an increased decline of FVC. Furthermore, we
showed that circulating IPF B-cells had elevated BTK
expression, which could contribute to a loss of immune
tolerance and development of autoimmunity in IPF
(Additional file 9, graphic summary). In a bleomycin pul-
monary fibrosis mouse model, we observed the induction
of IgA+ GC B-cells and IgA plasma cells, indicating
similarities with human pathobiology. The bleomycin
model also showed that proportions of BALF GC B-cells
correlated with the extent of fibrosis.
The increased numbers of TLOs in lungs of IPF pa-
tients, together with elevated serum CXCL13 and BAFF,
indicate involvement of B-cells in IPF [11–14]. The de-
crease in circulating transitional B-cells, together with
an increase of B cells in the lungs of IPF patients, sug-
gests migration from the blood towards the lungs. Tran-
sitional B-cells, which are immature B cells that have
recently emigrated from the bone marrow, are possibly
attracted to pulmonary TLO in IPF patients by CXCL13.
We confirmed that plasmablasts are increased in blood
[14], and importantly, also in IPF lungs. Furthermore,
DN-memory B-cells are increased blood of IPF patients.
This is particularly interesting as DN-memory B-cells ac-
tivate telomerase when stimulated and are thought to be
age-related exhausted memory B-cells [22, 23]. As both
telomerase dysfunction and immune exhaustion have
been implicated in IPF pathogenesis [24–26], this B-cell
subset would be an interesting topic for further research.
Repetitive alveolar epithelial injury exposes our im-
mune system to self-antigens, increasing the risk of in-
duction of autoreactive antibodies. Transforming growth
Fig. 4 More activated follicular helper T-cells (Tfh) in IPF lungs. (a) Representative gating strategy for identification of Tfh (CXCR5+CD45RA−CD4+)
and activated Tfh (CXCR5+CD45RA−CD4+PD-1HI) as depicted for a representative blood and lung single cell suspension for a control and IPF
patient. (b) Representative histogram overlay showing PD-1 expression levels of Tfh-cells depicted as MFI for a blood sample of an IPF patient
(gray), control lung (blue) and IPF lung (red). (c) Activated Tfh-cells as percentage of total Tfh-cells in single cell suspensions of control lungs (n =
8) and IPF lungs (n = 11). Non-parametric two-tailed Mann-Whitney test was used. Data are expressed as mean and dots represent individual
patient values. ** P < 0.01
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Fig. 5 Autoreactive IgA and IgG levels are higher in IPF and autoreactive IgA correlates with disease progression. (a) Total IgM, IgG, and IgA in
plasma of IPF patients and HCs. (b) Representative staining pattern of human epithelial cells (HEp)-2 slides with plasma of HC or IPF patients. First
row describes the number and percentage of patients with a positive staining and second row number and percentage of patients with a
specific antinuclear antibody (ANA) staining pattern. (c) Indirect quantification of auto-reactive immunoglobulins levels depicted as fluorescence
intensity for autoreactove-IgM, IgG and IgA assessed with HEp-2 staining. The fluorescence intensity of HEp2 slides was evaluated in an
automated and thus independent manner. The fluorescence intensity was corrected for number of HEp-2 cells per slide. A positive HEp-2 result
was set on 2x standard deviation above the mean of the HC for each immunoglobulin subtype (see also additional methods 1) (d) Pie-chart of
percentage of HC or IPF patients with detectable autoreactive antibodies and subclass (IgM, IgG and IgA (or combination)). (e) Increased
fluorescence intensity for plasma autoreactive IgA correlate with decline in forced vital capacity (FVC) over 1-year period. Data of 12 IPF patients
(with multidisciplinary diagnosis (MDD) of definitive or probable IPF) were used from our original cohort of 27 patients. 3 patients in the original
cohort died within one year and could not be used for this analysis. Correlation coefficients were calculated using Spearman’s rank method. Non-
parametric two-tailed Mann-Whitney test was used. Data are expressed as mean and dots represent individual patient values. * P < 0.05
** P < 0.01
Fig. 6 Increased Bruton’s tyrosine kinase (BTK) expression levels in B cells of IPF patients. (a) Mean fluorescence intensity (MFI) of BTK in all
circulating B-cells (CD19+) and (b) naïve B-cells (CD27−IgD+), IgD+ memory B-cells (CD27+IgD+) and IgD− memory B-cells (CD27+IgD−) of HCs and
IPF patients. (c) BTK expression (MFI) in pulmonary B-cells of control lungs and IPF lungs. Non-parametric two-tailed Mann-Whitney test was used.
Data are expressed as mean and dots represent individual patient values. * P < 0.05 ** P < 0.01
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factor-β, a key profibrotic cytokine, promotes IgA class-
switch recombination of B-cells [27, 28]. Serum IgA con-
centrations at the time of IPF diagnosis have been shown
to be a predictor of survival [29]. In our patient cohort,
plasma levels of total IgA and autoreactive IgA (mostly
recognizing ANA) were also enhanced and specifically
autoreactive IgA correlated with disease progression. Pre-
vious studies showed that autoantibodies found in IPF pa-
tients are often of the IgA subclass [8, 30]. Although
(autoreactive) IgG antibodies are also implicated in IPF
pathogenesis, we did not find a correlation with lung func-
tion decline [8, 9]. Autoreactive IgA may promote lung fi-
brosis through fibroblast proliferation and extracellular
matrix protein production [31, 32]., This leads to a detri-
mental feedforward loop as the profibrotic milieu in IPF
lungs promotes IgA class switching in B-cells.
BTK is a key molecule in BCR signaling and increased
BTK expression in B-cells promotes the development of
autoreactive B-cells [21]. Small-molecule BTK inhibitors
have been proven effective in the treatment of auto-
immune diseases in preclinical studies [21, 33]. In IPF
patients, BTK expression was increased in circulating B-
cells, especially in naïve B-cells. This might either reflect
global B-cell activation due to pro-inflammatory micro-
environments or pathogenic B-cell activation that dir-
ectly contributes to autoimmune pathology. Activated
Tfh-cells, which are present in IPF lungs, have the cap-
acity to engage with B-cells in the GCs of pulmonary
TLOs and might promote autoreactive B-cell develop-
ment [34]. Interestingly, mice with B-cell specific overex-
pression of BTK develop an autoimmune phenotype,
together with increased Tfh-cell proportions [35]. These
Tfh-cells might be induces by increased CD80 and
CD86 expression on B-cells, which provide costimula-
tory signals for T-cell activation [35]. Consequently, our
findings in IPF patients that (i) increased proportions of
circulating plasmablasts and (IgA-)memory B-cells with
(ii) enhanced BTK expression, (iii) augmented pulmon-
ary Tfh-cell activation, and (iv) enhanced plasma auto-
reactive IgA are present indicate an important role for
B-cells in IPF pathogenesis.
To investigate whether the same B-cell alterations
would occur in a well-established model for pulmonary
fibrosis, mice were exposed to bleomycin. Indeed,
Fig. 7 Bleomycin-induced fibrosis promotes germinal center IgA+ B-cells and IgA+ plasma cells. (a) Mice were sacrificed 21 days after saline or
bleomycin exposure and analyzed for fibrosis indices and inflammation. (b) Representative hematoxylin and eosin (h&e) staining of cryo-sections
of lung tissue after PBS or bleomycin exposure. Histological analysis revealed that pulmonary fibrosis was present in mice 21 days after bleomycin
exposure as shown by typical characteristics including thickening of alveolar walls with or without obvious damage and formation of fibrous
bands. The dashed square shows a probable TLO structure, which showed a center GL-7-positive cells (present on GC B-cells) surrounded by IgD-
positive naïve B-cells . (c) Total fibrosis score (TFS). The TFS is the product of the Ashcroft scale and level of lung involvement (see additional
methods 1). ((d) Proportion of GC B-cells (CD19+CD95+IgDlow), IgA GC B-cells (CD19+CD95+IgDlowIgA+), plasma cells (CD19lowCD138+), and IgA+
plasma cells (CD19lowCD138+IgA+) of alive cells in lungs. (e) Correlation of the proportion of GC B cells of alive cells in bronchoalveolar lavage
fluid (BALF) and TFS. Non-parametric two-tailed Mann-Whitney test was used. Correlation coefficients were calculated using Spearman’s rank
method. Data are expressed as mean and dots represent individual values of 4–7 mice per group and representative of 2 or more independent
experiments. * P < 0.05 ** P < 0.01 *** P < 0.001
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bleomycin exposure increases lung IgA+ GC B-cells and
IgA+ plasma cells. The degree of pulmonary fibrosis cor-
related with the frequencies of GC B-cells in BAL fluid.
This suggests that TLO formation with an active GC
and the presence of IgA+ GC B-cells reflects the degree
of pulmonary fibrosis. The local pro-fibrotic environ-
ment together with the pulmonary mucosal environment
is most likely responsible for the IgA class-switch
recombination.
The bleomycin model deviates from human IPF path-
ology as fibrosis development is not progressive and it
depends on inflammation [36]. Nevertheless, our data
show similarities with human B-cell pathobiology. A pre-
vious study explored the effects of the irreversible BTK-
inhibitor ibrutinib on fibrosis development and unex-
pectedly exacerbated fibrosis was found [37]. However,
the interpretation of this finding is complicated, because
ibrutinib is shown to have off-target effects and BTK is
also expressed in myeloid lineages [37, 38].
At this moment, it remains unclear if changes in B-cell
activation or subsets are the primary culprit for IPF dis-
ease onset and/or progression. Nevertheless, changes in
B-cell immunology may be a valuable biomarker for dis-
ease progression and/or survival, as high BAFF and
CXCL13 plasma concentrations, involved in B-cell acti-
vation and homing, are predictive for poor survival in
IPF patients [13, 14].
Rituximab, an antibody against CD20 which destroys
CD20+ B cells, is effective in the treatment of several auto-
immune diseases [39]. Compared to a historical cohort, an
improvement of gas exchange and clinical outcome was ob-
served in IPF patients with an acute exacerbation treated
with rituximab, together plasma exchange and intravenous
immune globulin [15]. The same experimental therapy is
now under investigation in patients with acute exacerba-
tions of IPF in a phase 2 trial (NCT03286556). If rituximab
alone could be beneficial in the era of anti-fibrotic drugs is
also currently examined and the results of this trial are ex-
pected in 2020 (NCT01969409). We believe that rituximab
or other B-cell modulating therapies could be of value in
the treatment of IPF patients next to ‘anti-fibrotic’ medica-
tion. Large landmark trials in the past using broad acting
anti-inflammatory molecules in unselected IPF patients
have learned that “one size fits all” approach does not
always work [7]. Therefore, in our opinion, selection of IPF
patients eligible for B-cell modulating therapies should be
based on inflammatory biomarkers, preferably those that
reflect B-cell (auto-) reactivity or activations status.
Our study has some limitations: First, lungs of diseased
patients who underwent surgery, were used as controls.
Three of these controls had mild COPD. We cannot rule
out that inflammation profiles are affected, as recent lit-
erature show an increase of IgA expression and accumula-
tion of B-cells in lung TLO in patients with severe COPD
[40, 41]. However, subgroup-analysis showed that the
COPD lungs had similar outcomes in B-cell subsets and
activation markers compared with other controls (data
not shown). Using disease controls could also contribute
similar BTK expression in pulmonary B-cells in IPF pa-
tient and controls, as the majority of pulmonary B-cells
have been activated. Second, no differences in B-cell sub-
sets were observed in LN in our human data. The IPF LN
examined in this study came from transplanted IPF pa-
tients, indicating end-stage IPF, which could be different
in T- and B-cell proportions compared to LNs in early IPF
disease. TLOs persist and accumulate during disease pro-
gression in IPF lungs, which may suggest that local im-
mune activation becomes more important in end-stage
disease [11]. Furthermore, LN enlargement does not ne-
cessarily change the proportion of B-cell subsets. Third,
the relatively small sample size of human IPF lungs and
LN used in our experiments. To the best of our know-
ledge, our study is the first that assessed B-cell subsets and
activation in explanted IPF lungs and LN by detailed flow
cytometry profiling and significant differences could be
observed. Fourth, potential confounding by subject drop-
out in the 1-year FVC change correlation analysis, as 4
patients died within the first year. Finally, two specimens
(one IPF blood sample and one control lung) were
obtained from subjects with a history of auto-immune dis-
ease. These samples were not excluded as (i) both subjects
did not use immunomodulating medication, (ii) showed
no clinically active disease at the time of sample collection,
and (iii) the obtained B-cell data were within the range of
the other samples.
Conclusion
We provide evidence that (autoreactive) B-cells, espe-
cially IgA-memory B-cells, are increased in IPF patients,
possibly driven by increased intracellular BTK expres-
sion. Additionally, autoreactive IgA could be a predictor
for FVC decline, however larger validation studies are
needed to investigate the potential of autoreactive IgA as
a new biomarker in IPF.
There is a need for stratified medicine based on
inflammatory biomarkers and profiles to select pa-
tients with IPF who may be eligible for co-treatment
with anti-inflammatory or immunomodulating ther-
apies next to ‘anti-fibrotic’ medication. Our study
provides a rationale for B-cell modulating therapies
in selected IPF patients.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12931-019-1195-7.
Additional file 1: Figure S1. No changes of proportions of total B-cells be-
tween controls and IPF patients. Flow cytometric quantification of total B-cells
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(CD19+) in blood, lungs and lymph nodes (LN) as percentage of alive cells. For
blood samples data also depicted as absolute number of B-cells per ml blood.
Data are expressed as mean and dots represent individual values
Additional file 2: Figure S2. No alterations in B-cell subsets between
control lymph nodes (LN) and IPF LN. Flow cytometric quantification of
naïve B-cells (CD19+IgD+CD27-) IgD+ and IgD− memory CD27+ B-cells,
double negative (DN) B-cells (CD19+IgD−CD27−), transitional B-cells
(CD19+CD24+CD38+), and plasmablast (CD19+CD38+CD27+) as percent-
age of alive cells. Data are expressed as mean and dots represent individ-
ual values.
Additional file 3: Figure S3. Augmented proportions of IgA-
expressing CD27+ memory B-cell subsets. (A) Representative gating
strategy for the identification of surface IgA expression on CD27+IgD−
memory B-cells. The CD27+IgD−IgM−IgG− memory cells are enriched
for IgA+ surface expression as depicted for a healthy control (HC)
and IPF patient. (B) Flow cytometric analysis of the distribution of
surface expression of IgD, IgM, IgG and IgA on CD27+ memory B-
cells for blood, lungs and lymph nodes for controls and IPF patients.
Non-parametric two-tailed Mann-Whitney test was used. ** P < 0.01
*** P < 0.001
Additional file 4: Figure S4. Augmented proportions of IgA-expressing
DN memory B-cell subsets. (A) Representative gating strategy for the
identification of surface IgA expression on double negative (DN) memory
B-cells (CD19+CD27−IgD−). The IgM−IgG− DN memory cells are enriched
for IgA+ surface expression as depicted for a healthy control (HC) and IPF
patient. (B) Flow cytometric analysis of the distribution of surface expres-
sion of IgM, IgG and IgA on DN memory B-cells for blood, lungs and
lymph nodes for controls and IPF patients. Non-parametric two-tailed
Mann-Whitney test was used. ** P < 0.01 *** P < 0.001
Additional file 5: Figure S5. Increased total IgG and IgA in plasma of IPF
patients. (A) total plasma IgM, IgG and IgA levels (μg/ml) for HC and IPF
patients. (B) Correlation between total IgG or IgA (μg/ml) and autoreactive
IgG or IgA. Indirect quantification of auto-reactive immunoglobulin levels
depicted as fluorescence intensity measured on HEp-2 slides. Non-
parametric two-tailed Mann-Whitney test was used. Correlation coefficients
were calculated using Spearman’s rank method. Data are expressed as mean
and dots represent individual patient values. * P < 0.05 ** P < 0.01.
Additional file 6: Figure S6. Autoreactive IgG and IgM does not
correlate with disease progression. Fluorescence intensity for plasma
autoreactive IgG (A) and IgM (B) does not correlate with decline in forced
vital capacity (FVC) over 1-year period in IPF patients. Correlation coeffi-
cients were calculated using Spearman’s rank method.
Additional file 7: Figure S7. Gating strategy for B-cell subsets in mice.
Representative gating strategy used for mice experiments for the identifi-
cation of GC B-cells (CD19+CD95+IgDlow), IgA GC B-cells (CD19+CD95+Ig-
DlowIgA+), plasma cells (CD19lowCD138+) and IgA+ plasma cells
(CD19lowCD138+IgA+).
Additional file 8: Figure S8. Increased proportions of IgA+ GC B-cells
and IgA+ plasma cells in lungs in mice exposed to saline and bleomycin. (A)
Flow cytometric quantification of IgA+ GC B-cells (CD19+CD95+IgDlowIgA+)
as percentage of GC B-cells and (B) IgA+ plasma cells (CD19lowCD138+IgA+)
as percentage of plasma cells in lungs of mice exposed to saline or bleo-
mycin. Data are expressed as mean and dots represent individual patient
values. Nonparametric two-tailed Mann-Whitney test was used. * P < 0.05
Additional file 9:. Graphic summary of B-cell subset alterations and
autoreactive IgA induction in IPF patients. Immature B cells leave the
bone marrow as transitional B-cells for further differentiation. Decrease in
circulating transitional B-cells together with their increase in IPF lungs
suggest homing towards pulmonary tertiary lymphoid organs (TLO). In-
creased BTK levels in (immature) B-cells hinders adequate elimination of
autoreactive B-cells to (pulmonary) self-antigens and might contribute to
the development of autoreactive B-cells in pulmonary TLOs after epithe-
lial injury. Furthermore, activated (PD-1 high) Tfh-cells are present in IPF
lungs and they engage with B-cells in the GC of pulmonary TLOs, pos-
sibly further promoting autoreactive B-cell development. Cytokines pro-
duced by Tfh-cells and the local environment in IPF lungs induces
predominantly IgA class-switch recombination. Upon activation, IgA
memory B-cells and plasmablast leave pulmonary TLO leading to an
increase of IgA memory B-cells, plasmablasts and free (autoreactive) IgA
in blood of IPF patients.
Additional file 10: Table S1. Overview of antibodies used for
experiments.
Additional file 11: Methods S1. Procedures of mouse experiments.
Abbreviations
ANA: Antinuclear antibody; BAFF: B-cell activating factor; BALF: Broncho
alveolar lavage fluid; BCR: B-cell receptor; CXCL: CXC chemokine ligand;
DN: Double negative; EDTA: Ethylenediaminetetraacetic acid; FVC: Forced
vital capacity; HC: Healthy control; HEp-2: Human epithelial cells;
IPF: Idiopathic pulmonary fibrosis; LN: Lymph Node; MFI: Mean fluorescence
intensity; PBS: Phosphate buffered saline; RPMI: Roswell Park Memorial
Institute; Tfh: Follicular helper T-cells; TFS: Total fibrosis score; TLO: Tertiary
lymphoid organ
Availability of data and material
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributionsa
P.H., B.v.d.B., R.W.H., M.S.W., M.K. conceived of the project. P.H., J.A.C., M.v.N.,
C.E.B., B.N.M., J.H.v.d.T., R.A.H., B.v.d.B., J.R.M., S.F.N., O.B.C., R.W.H., M.S.W., M.K.
generated data for the project; P.H., J.A.C., M.K. analyzed data for the project;
P.H., M.K. wrote the manuscript; P.H., J.A.C., M.v.N., C.E.B., B.N.M., J.H.v.d.T.,
R.A.H., B.v.d.B., J.R.M., S.F.N., O.B.C., R.W.H., M.S.W., M.K. reviewed and edited
the manuscript, gave final approval for submission, and were accountable for
all aspects of the work in terms of ensuring accuracy of the data.
Conflict of interest
The authors declare no conflict of interest.
Funding
This study was not financially supported.
Ethics approval and consent to participate
The Medical Ethical Committee of the Erasmus MC Rotterdam approved this
study (METC 2012–512). Informed consent was obtained from every
participant and healthy control (HC) before collection of blood samples.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Pulmonary Medicine, Erasmus Medical Center,
‘s-Gravendijkwal 230, 3015, CE, Rotterdam, The Netherlands. 2Department of
Pharmacokinetics, Toxicology and Targeting, University of Groningen,
Groningen, The Netherlands. 3Department of Pathology, Erasmus Medical
Center, Rotterdam, The Netherlands. 4Promedior Inc, Lexington, MA, USA.
5Department of Pulmonary Medicine, Amphia hospital Breda, Breda, The
Netherlands. 6GRIAC research Institute, University of Groningen, University
Medical Center Groningen, Groningen, The Netherlands.
Received: 17 July 2019 Accepted: 23 September 2019
References
1. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An
Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of
Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice
Guideline. Am J Respir Crit Care Med. 2015;192(2):e3–19.
2. Raghu G Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, et al.
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis:
evidence-based guidelines for diagnosis and management. Am J Respir Crit
Care Med. 2011;183(6):788-824
3. du Bois RM. An earlier and more confident diagnosis of idiopathic
pulmonary fibrosis. Eur Respir Rev. 2012;21(124):141–6.
Heukels et al. Respiratory Research          (2019) 20:232 Page 12 of 13
4. Wick G, Grundtman C, Mayerl C, Wimpissinger TF, Feichtinger J, Zelger B,
et al. The immunology of fibrosis. Annu Rev Immunol. 2013;31:107–35.
5. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg
MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic
pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.
6. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al.
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J
Med. 2014;370(22):2071–82.
7. Heukels P, Moor CC, von der Thusen JH, Wijsenbeek MS, Kool M.
Inflammation and immunity in IPF pathogenesis and treatment. Respir Med.
2019;147:79–91.
8. Hoyne GF, Elliott H, Mutsaers SE, Prele CM. Idiopathic pulmonary fibrosis
and a role for autoimmunity. Immunol Cell Biol. 2017;95(7):577–83.
9. Feghali-Bostwick CA, Tsai CG, Valentine VG, Kantrow S, Stoner MW, Pilewski
JM, et al. Cellular and humoral autoreactivity in idiopathic pulmonary
fibrosis. J Immunol. 2007;179(4):2592–9.
10. Marchal-Somme J, Uzunhan Y, Marchand-Adam S, Valeyre D, Soumelis V,
Crestani B, et al. Cutting edge: nonproliferating mature immune cells form a
novel type of organized lymphoid structure in idiopathic pulmonary fibrosis.
J Immunol. 2006;176(10):5735–9.
11. Todd NW, Scheraga RG, Galvin JR, Iacono AT, Britt EJ, Luzina IG, et al.
Lymphocyte aggregates persist and accumulate in the lungs of patients
with idiopathic pulmonary fibrosis. J Inflamm Res. 2013;6:63–70.
12. Havenar-Daughton C, Lindqvist M, Heit A, Wu JE, Reiss SM, Kendric K, et al.
CXCL13 is a plasma biomarker of germinal center activity. Proc Natl Acad
Sci U S A. 2016;113(10):2702–7.
13. Vuga LJ, Tedrow JR, Pandit KV, Tan J, Kass DJ, Xue J, et al. C-X-C motif
chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med. 2014;189(8):966–74.
14. Xue J, Kass DJ, Bon J, Vuga L, Tan J, Csizmadia E, et al. Plasma B lymphocyte
stimulator and B cell differentiation in idiopathic pulmonary fibrosis
patients. J Immunol. 2013;191(5):2089–95.
15. Donahoe M, Valentine VG, Chien N, Gibson KF, Raval JS, Saul M, et al.
Autoantibody-targeted treatments for acute exacerbations of idiopathic
pulmonary fibrosis. PLoS One. 2015;10(6):e0127771.
16. Mohammed AGA, Alshihre A, Al-Homood IA. Rituximab treatment in
patients with systemic sclerosis and interstitial lung disease. Ann Thorac
Med. 2017;12(4):294–7.
17. Sharp C, McCabe M, Dodds N, Edey A, Mayers L, Adamali H, et al. Rituximab
in autoimmune connective tissue disease-associated interstitial lung disease.
Rheumatology (Oxford). 2016;55(7):1318–24.
18. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official
ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based
guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;
183(6):788–824.
19. Heukels P, van Hulst JAC, van Nimwegen M, Boorsma CE, Melgert BN, van
den Toorn LM, et al. Fibrocytes are increased in lung and peripheral blood
of patients with idiopathic pulmonary fibrosis. Respir Res. 2018;19(1):90.
20. Vinuesa CG, Linterman MA, Yu D, MacLennan IC. Follicular helper T cells.
Annu Rev Immunol. 2016;34:335–68.
21. Corneth OBJ, Verstappen GMP, Paulissen SMJ, de Bruijn MJW, Rip J, Lukkes
M, et al. Enhanced Bruton's tyrosine kinase activity in peripheral blood B
lymphocytes from patients with autoimmune disease. Arthritis Rheumatol.
2017;69(6):1313–24.
22. Martorana A, Balistreri CR, Bulati M, Buffa S, Azzarello DM, Camarda C, et al.
Double negative (CD19+IgG+IgD-CD27-) B lymphocytes: a new insight from
telomerase in healthy elderly, in centenarian offspring and in Alzheimer's
disease patients. Immunol Lett. 2014;162(1 Pt B):303–9.
23. Colonna-Romano G, Bulati M, Aquino A, Pellicano M, Vitello S, Lio D, et al. A
double-negative (IgD-CD27-) B cell population is increased in the peripheral
blood of elderly people. Mech Ageing Dev. 2009;130(10):681–90.
24. van Deursen JM. The role of senescent cells in ageing. Nature. 2014;
509(7501):439–46.
25. Snetselaar R, van Batenburg AA, van Oosterhout MFM, Kazemier KM,
Roothaan SM, Peeters T, et al. Short telomere length in IPF lung associates
with fibrotic lesions and predicts survival. PLoS One. 2017;12(12):e0189467.
26. Newton CA, Zhang D, Oldham JM, Kozlitina J, Ma SF, Martinez FJ, et al.
Telomere Length and Use of Immunosuppressive Medications in Idiopathic
Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019;200(3):336-47.
27. Cerutti A. The regulation of IgA class switching. Nat Rev Immunol.
2008;8(6):421–34.
28. Pilette C, Ouadrhiri Y, Godding V, Vaerman JP, Sibille Y. Lung mucosal
immunity: immunoglobulin-a revisited. Eur Respir J. 2001;18(3):571–88.
29. Ten Klooster L, van Moorsel CH, Kwakkel-van Erp JM, van Velzen-Blad H,
Grutters JC. Immunoglobulin a in serum: an old acquaintance as a new
prognostic biomarker in idiopathic pulmonary fibrosis. Clin Exp Immunol.
2015;181(2):357–61.
30. Taille C, Grootenboer-Mignot S, Boursier C, Michel L, Debray MP, Fagart J,
et al. Identification of periplakin as a new target for autoreactivity in
idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.
2011;183(6):759–66.
31. Arakawa S, Suzukawa M, Watanabe K, Kobayashi K, Matsui H, Nagai H, et al.
Secretory immunoglobulin A induces human lung fibroblasts to produce
inflammatory cytokines and undergo activation. Clin Exp Immunol. 2019;
195(3):287-301.
32. Wallace WA, Howie SE. Upregulation of tenascin and TGFbeta production in
a type II alveolar epithelial cell line by antibody against a pulmonary auto-
antigen. J Pathol. 2001;195(2):251–6.
33. Corneth OBJ, Klein Wolterink RGJ, Hendriks RW. BTK signaling in B cell
differentiation and autoimmunity. Curr Top Microbiol Immunol.
2016;393:67–105.
34. Crotty S. T follicular helper cell differentiation, function, and roles in disease.
Immunity. 2014;41(4):529–42.
35. Corneth OB, de Bruijn MJ, Rip J, Asmawidjaja PS, Kil LP, Hendriks RW.
Enhanced expression of Bruton's tyrosine kinase in B cells drives systemic
autoimmunity by disrupting T cell homeostasis. J Immunol.
2016;197(1):58–67.
36. Tashiro J, Rubio GA, Limper AH, Williams K, Elliot SJ, Ninou I, et al. Exploring
animal models that resemble idiopathic pulmonary fibrosis. Front Med
(Lausanne). 2017;4:118.
37. Gu Y, Huang B, Yang Y, Qi M, Lu G, Xia D, et al. Ibrutinib exacerbates
Bleomycin-induced pulmonary fibrosis via promoting inflammation.
Inflammation. 2018;41(3):904–13.
38. Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B
cells and malignancies. Mol Cancer. 2018;17(1):57.
39. Gurcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A
review of the current use of rituximab in autoimmune diseases. Int
Immunopharmacol. 2009;9(1):10–25.
40. Polverino F, Cosio BG, Pons J, Laucho-Contreras M, Tejera P, Iglesias A, et al.
B cell-activating factor. An orchestrator of lymphoid follicles in severe
chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;
192(6):695–705.
41. Ladjemi MZ, Martin C, Lecocq M, Detry B, Aboubakar Nana F, Moulin C,
et al. Increased IgA expression in lung lymphoid follicles in severe COPD.
Am J Respir Crit Care Med. 2019;199(5):592-02.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Heukels et al. Respiratory Research          (2019) 20:232 Page 13 of 13
